Nintx

Nintx (Next Innovative Therapeutics) was originated in Brazil at the beginning of 2021 to translate complex biological interactions (plants, microorganisms, and humans) into novel therapies with environmental and social impact. To that end, Nintx has established partnerships with research institutes, private companies and investment funds that bring both complementary expertise and financial resources. Nintx develops a new generation of medicines leveraging biodiversity, primarily from Brazil, targeting multifactorial diseases, caused by genetic and environmental factors as well as their interactions via the human gut microbiome. Nintx owns cutting-edge proprietary technologies, an Agentic AI platform (GAIApath®) and an artificial gut (xGIbiomics®), that enable the development of innovative ingredients (pharmaceuticals and nutraceuticals).